tbuckley/cabot-search huggingface dataset:
Lymphoscintigraphy
Authors: ROBER G. WELLS, JAMES A. RUSKIN, JOHN R. STY
Journal: Clinical Nuclear Medicine (1986)

Congenital lymphangioma is a relatively common cause of childhood soft tissue masses of the extremities. Radionuclide pedal lymphangiography is a simple and rapid technique for the diagnosis of lymphangiomas of the lower extremities. A case of congenital lymphangioma of the thigh in an eight-year-old child is illustrated.
Abstract 4668: A next generation sequencing assay to detect the fusion products of ALK, ROS1 and RET with any fusion partner genes and hotspot mutations in FFPE samples
Authors: Qiang Xu, Guan Wang, Bo Li, Maoxiang Qian, Douglas Fang, Lele Sun, Yundi Chen, Hongye Sun
Journal: Cancer Research (2014)

Abstract Targeted drugs have been widely used in the treatment of lung cancer, especially for non small cell lung cancer (NSCLC) patients. NCCN guideline lists multiple drugs which are particularly effective in the subgroup of patients with specific gene mutation variants, including the fusion transcripts of ALK, ROS1 and RET, and the mutations of EGFR, KRAS, BRAF and HER2. Multiple techniques have been developed to detect fusion transcripts in tumor samples, such as FISH, IHC and PCR assays. FISH is the most accurate method for fusion detection currently. The split probe FISH assay, which does not require the pre-knowledge of what is the fusion partner with ALK for example, can detect unknown ALK fusion products as well. However, it fails to identify which gene is fused with ALK (or other oncogene) in the chimera products, therefore is not informative for the mechanism or drug resistance study. In addition, due to the limitation on the fluoresce dye, it is quite difficult to multiplex fusion FISH probes for different genes into one assay. We describe here a next generation sequencing assay to detect a panel of fusion transcripts and mutations in one single assay. Our single assay can detect the fusion products of ALK, ROS1 and RET with any known or unknown fusion partners, together with the hotspot mutations in EGFR, KRAS, BRAF and HER2. Our assay can identify not only the exact sequence of the unknown fusion partners, but also any mutations within the full coding regions of ALK, ROS1 and RET. This information is critical for the resistance mechanism study and the next generation inhibitor drug development, since about half of the ALK inhibitor resistance was caused by the mutations in ALK gene itself. We have identified a novel ALK fusion gene with a never-reported fusion partner in a lung cancer patient. The xenograft model derived from this patient responds to crizotinib well in the in vivo study (published on Journal of Thoracic Oncology). We have demonstrated that our assay can reliably detect both the novel fusion and the well known EML4-ALK fusion from only 1-2 5um FFPE slides of the lung tumor tissues, together with other possible fusions and mutations as well. Note: This abstract was not presented at the meeting. Citation Format: Qiang Xu, Guan Wang, Bo Li, Maoxiang Qian, Douglas Fang, Lele Sun, Yundi Chen, Hongye Sun. A next generation sequencing assay to detect the fusion products of ALK, ROS1 and RET with any fusion partner genes and hotspot mutations in FFPE samples. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4668. doi:10.1158/1538-7445.AM2014-4668
Evaluation of Peripheral Vascular Disease-Reply
Authors: Stefan A. Carter
Journal: JAMA (1982)

In Reply.—  Dr LeMaitre's letter is of value in drawing the attention of the profession to the use of walking and postexercise measurements of the ankle pressures in the assessment of patients with leg pain, which may or may not be due to arterial obstruction. Most physicians would agree with his general approach and the statement that one should not submit a patient to angiography, nor carry out surgery unless the claudication is disabling.  Certain points are worth considering in relation to his protocol.   The use of walking and measurement of ankle pressures has been well documented1 and is of particular value in the differential diagnosis of pseudoclaudication, which may be due to spinal or musculoskeletal disorders, and in patients in whom arterial obstruction may coexist. In the latter cases careful history is of paramount importance.    Since patients with peripheral vascular disease often have an overt or subclinical
Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin
Authors: Y. Niwa, T. Terashima, H. Sumi
Journal: British Journal of Dermatology (2003)

Tacrolimus, produced by the fungus Streptomyces tsukabaensis, is a potent macrolide immunosuppressant widely used in liver and kidney transplantation. Topical tacrolimus has recently been found to be an effective treatment for atopic dermatitis (AD).Because of the well-known association between T-cell immunosuppression and an increased risk of carcinogenesis, we investigated the effect of topical tacrolimus on skin carcinogenesis in 117 mice.Approximately 8 cm2 of the shaved dorsal skin of 7-week-old female CD-1 mice was treated with 7,12-dimethylbenz[alpha]anthracene (DMBA) dissolved in acetone, which is in general use as a tumour initiator, or acetone alone, on day 1 of the experiment, followed by promoting treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA) with or without tacrolimus, or acetone with or without tacrolimus, for 20 weeks. The mice were divided into six treatment groups: (1) DMBA followed by acetone; (2) DMBA followed by TPA; (3) DMBA followed by acetone + tacrolimus; (4) DMBA followed by TPA + tacrolimus; (5) acetone followed by acetone + tacrolimus; and (6) acetone followed by acetone (control).The induction of skin tumours was significantly greater in the TPA-treated groups than in the absence of TPA. However, after 14 weeks there was marked synergy between tacrolimus and the DMBA/TPA regimen, with 0.47 +/- 0.13 (mean +/- SD) new tumours per mouse per week in group 4 vs. 0.10 +/- 0.025 in group 2 (P < 0.01), and 0.01 +/- 0.002 in group 3. A significant reduction in the CD4/CD8 ratio was found in axillary and inguinal lymph nodes in tacrolimus-treated mice, supporting the presumption that the immunosuppressive effect of the drug was responsible for its effect in promoting tumorigenesis. The major increase in tumours caused by topical tacrolimus was of papillomas, not squamous cell carcinomas. Papillomas are uncommon in humans, and are benign. However, 8.5% of the tumours found in the experiment were squamous cell carcinomas, and a considerable synergy between topical tacrolimus and conventional carcinogens was observed, raising the spectre of some risk of skin carcinogenesis in AD patients undergoing prolonged treatment with tacrolimus.Caution and careful surveillance are required with regard to skin lesions in patients treated with tacrolimus for prolonged periods.
IL-13–induced airway mucus production is attenuated by MAPK13 inhibition
Authors: Yael G. Alevy, Anand C. Patel, Arthur G. Romero, Dhara A. Patel, Jennifer Tucker, William T. Roswit, Chantel A. Miller, Richard F. Heier, Derek E. Byers, Tom J. Brett, Michael J. Holtzman
Journal: Journal of Clinical Investigation (2012)

Increased mucus production is a common cause of morbidity and mortality in inflammatory airway diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. However, the precise molecular mechanisms for pathogenic mucus production are largely undetermined. Accordingly, there are no specific and effective anti-mucus therapeutics. Here, we define a signaling pathway from chloride channel calcium-activated 1 (CLCA1) to MAPK13 that is responsible for IL-13–driven mucus production in human airway epithelial cells. The same pathway was also highly activated in the lungs of humans with excess mucus production due to COPD. We further validated the pathway by using structure-based drug design to develop a series of novel MAPK13 inhibitors with nanomolar potency that effectively reduced mucus production in human airway epithelial cells. These results uncover and validate a new pathway for regulating mucus production as well as a corresponding therapeutic approach to mucus overproduction in inflammatory airway diseases.
Detection of myocardial ischemia with dynamic SPECT I-123-lodophenylpentadecanoic acid (IPPA) imaging
Authors: Edouard Daher, Cindy Q.X. Shi, Eliot N. Heller, Yi-Hwa Liu, Paul DeMan, Donald P. Dione, Frans J.Th. Wackers, Albert J. Sinusas
Journal: Journal of the American College of Cardiology (1996)
Comment on “Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008” by Dellinger et al.
Authors: A. M. E. Spoelstra - de Man, A. R. J. Girbes
Journal: Intensive Care Medicine (2008)

We read with interest the recent revision of the Surviving Sepsis Campaign (SSC) guidelines by Dellinger et al. [1].The use of the GRADE system to classify the strength of the recommendations has certainly improved the guidelines.However, we regret that not all guidelines were adjusted according to the current literature.First of all, the absence of a recommendation regarding selective digestive tract decontamination (SDD) is striking.The guidelines group was evenly split, with equal numbers weakly in favor and against recommending the use of SDD.This is remarkable, since SDD is one of the best ever evaluated therapies in intensive care medicine, with more than 50 randomized controlled trials and 10 meta-analyses showing that SDD reduces pneumonia by 65% and mortality by 22% [2].The authors gave several reasons why they chose not to recommend SDD in their guidelines.They argue that no studies regarding SDD specifically focused on septic patients.However, several other guidelines based on general ICU populations (i.e., stress ulcer prophylaxis, deep vein thrombosis prophylaxis, glucose
Comparison of 11–201 Renal Uptake with Tc-99m DTPA Angiorenography in Patients with Hypertension Measures of Renal Asymmetry
Authors: GILBERT A. HURWITZ, JOHN E. POWE, CARL A. WESOLOWSKI, ADELG. MATTAR
Journal: Clinical Nuclear Medicine (1992)

Renal uptake of TI-201 reflects renal perfusion and may have a role in defining renal asymmetry in patients with hypertension who are referred for myocardial scintigraphy. The authors compared two methods of quantitating differential renal uptake of TI-201, with similar data obtained from the angiographic and renal uptake (RU) phases of Tc-99m DTPA scintigraphy in 35 patients with hypertension. For TI-201, asymmetry in renal counts was quantitated based on a simple outline technique or on interpolative background subtraction of 5-minute posterior images. Inter-observer and intra-observer variability among duplicate measurements were lower for TI-201, particularly with interpolative background subtraction, than for Tc-99m DTPA. Renal/background ratios were similar for TI-201 and RU-phase Tc-99m DTPA images when considering liver, spleen, or inter-renal regions as background; however, paraspinal uptake was relatively higher with TI-201 (P < 0.01). Qualitatively, renal asymmetry scores with the two radiotracers agreed (r = 0.89, blinded readings by four observers), although asymmetry was more marked with TI-201 (P = 0.06). Measurements with TI-201 agreed with both phases of Tc-99m DTPA (r = 0.96 to 0.98), but interpolative background subtraction systematically yielded greater inter-renal asymmetry than RU (P < 0.01), reflecting the qualitative impression. Thus, ancillary TI-201 imaging reflects differences between the kidneys in a fashion similar but not identical to Tc-99m DTPA scintigraphy.
Psychosocial Risk Factors for Cardiovascular Disease
Authors: Redford B. Williams, John C. Barefoot, Neil Schneiderman
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Closing the gap between professional teaching and practice
Authors: L. Doyal
Journal: BMJ (2001)

Papers p 709 Personal view p 743 Learning to be a doctor can be uniquely rewarding. Unlike other undergraduate study, clinical medicine has a practical edge such that students can directly experience the relevance of their academic work through their educational contact with patients. They also have the privilege of experiencing the range of human intellect, emotion, achievement, and failure embodied in the patients from whom they will learn. Finally, their positive interactions with patients reinforce the altruism that brought many of them into medicine. At its best, medical education can make students feel good about themselves and what they are learning, as well as preparing them for good professional practice. But if a gap exists between their clinical teaching and what they know and feel to be morally right the effects can be disastrous.1 #### Policy on the rights of patients in medical education For educational activities not part of clinical care:
Mittelschmerz is a preovulatory symptom.
Authors: C O'Herlihy, H P Robinson, L J de Crespigny
Journal: BMJ (1980)

about the true paternity of the pregnancy that was affected with eclampsia.They were interviewed either antepartum, postpartum, or at a postnatal visit, but always after confidentiality had been established.The questioning was either direct or oblique, depending on my assessment of the patient's personality.The placenta was examined after delivery in all cases to exclude gross placental abnormalities such as hydatidiform mole coexisting with a normal fetus.To assess the prevalence of change of paternity in this area two random groups of 300 and 200 pregnant multiparous patients were questioned in 1971 and 1977 respectively.Thirty-four (74 %) out of the 46 multiparous eclamptic patients seen in my practice during the 10 years admitted that they had had a new partner for the affected pregnancy.Four were not sure, and eight were certain that there was no new factor in the affected pregnancy, which varied between their 3rd and 8th.In 20 cases the fact of a new partner was easily elicited during routine history taking, and subsequent interview was unnecessary.These new partnerships were owing either to death of the previous husband, separation, divorce and remarriage, unfaithfulness, or unmarried multi- parous patients (Nrachi custom practised by the Igbo people).So far 14 of these patients have had subsequent deliveries under my supervision.Three had oedema and albuminuria but none had a recurrence of eclampsia.Two of them reported another change of partner.Of the random groups of 300 and 200 women questioned in 1971 and 1977, respectively, for change of paternity, 31 and 12 had had changes in the preceding three years.Out of these 43, one had had intrapartum eclampsia and three had had only albuminuria and ankle oedema in their pregnancies.
Abstract 2848: Preclinical activity of OM-RCA-01, a humanized anti-FGFR1 antibody, in renal cell carcinoma (RCC)
Authors: Ilya V. Tsimafeyeu, Elina Zaveleva, Walter Low
Journal: Cancer Research (2012)

Abstract Background: Fibroblast growth factor (FGF) receptor 1 (FGFR1) is a potential therapeutic target for treatment of metastatic RCC. Early we reported that anti-FGFR1 monoclonal antibody inhibited ligand-induced phosphorylation of FGFR1, activation of MAP kinase and Akt downstream signaling pathways in FGFR1 expressing endothelial (bovine adrenal cortex capillary endothelial cells) and human RCC (Caki-1) lines (Tsimafeyeu et al. AACR/JCA joint conference 2010). Today we investigated the preclinical activity of OM-RCA-01, a novel therapeutic humanized anti-FGFR1 antibody with high affinity (Kd of 1.59 nM), in RCC. Methods: To assess the effect of anti-FGFR1 antibody on FGF-mediated signaling, the human renal carcinoma Caki-1 FGFR1-expressing cells were incubated (0.5% FBS) and were dosed with OM-RCA-01 at 100, 10, and 1 mcg/ml. Control wells were left untreated. Three hours after dosing, basic FGF was added at a concentration of 50 ng/ml. Additional control wells were treated with OM-RCA-01 without FGF-stimulation. Cell growth inhibition was determined using Promega's Cell Titer-Glo® assay. Charles River female NCr nu/nu mice (6-12 weeks of age) were set up with 1 mm3 Caki-1 tumor fragments sc in flank. Tumor sizes were measured in a blind fashion twice a week with a vernier caliper. Mice with established tumors (an average size of 80 - 120 mg) were randomly divided into vehicle, non-specific IgG or OM-RCA-01 groups per 10 animals in group. Animals were treated with antibody using different doses (1 or 10 mg/kg). Endpoint was significant differences in tumor growth delay. Results: In vitro study showed that basic FGF significantly increased proliferation of the human FGFR1-expressing renal carcinoma cells (P=0.011). No effect of basic FGF on cell line proliferation was observed when the cells were incubated with OM-RCA-01 antibody at any concentrations up to 100 mcg/kg in comparison with FGF-untreated control (P=0.855). In vivo, the tumors in untreated mice or mice treated with non-specific IgG continued their aggressive growth to reach the size of 2000 cm3, at which point the mice were killed. In contrast, treatment with OM-RCA-01 not only significant arrested further growth of the tumors (P=0.006) but also demonstrated differences in tumor volume compared with vehicle already on Day 13. A similar anti-tumor activity of OM-RCA-01 was observed when the antibody was given in low (1 mg/kg) or high (10 mg/kg) doses (P=0.917). Conclusions: High-affinity humanized anti-FGFR1 antibody OM-RCA-01 suppressed ligand-induced proliferation of human RCC cells in vitro. OM-RCA-01 has significant early anti-tumor efficacy in Caki-1 xenograft model. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2848. doi:1538-7445.AM2012-2848
Modulation of collagen synthesis and mRNA by continuous and intermittent use of topical hydrocortisone in human skin
Authors: P. Nuutinen, R. Riekki, M. Parikka, T. Salo, P. Autio, J. Risteli, A. Oikarinen
Journal: British Journal of Dermatology (2003)

Glucocorticoids have been shown to downregulate collagen synthesis in human skin in vivo, thereby contributing to skin atrophy.To compare the effects of continuous and intermittent use of topical hydrocortisone on skin collagen synthesis and, furthermore, to elucidate the mechanism of collagen synthesis reduction induced by hydrocortisone.Collagen propeptides reflecting the synthesis rate of type I and III collagens were studied from suction blister fluids in nine healthy subjects after 3 weeks of continuous (twice daily) or intermittent (on three consecutive days weekly) topical hydrocortisone treatment and 2 weeks after the termination of treatment. Type I collagen mRNA was studied in the same subjects from skin biopsies by using in situ hybridization (ISH) after 3 weeks of treatment.Three weeks of continuous treatment decreased the types I and III collagen propeptides in suction blister fluid by 89% and 82%, respectively, while intermittent treatment resulted in a corresponding decrease of 53% and 50%. ISH studies from skin biopsies showed type I collagen mRNA to be markedly reduced in fibroblasts after continuous and intermittent steroid treatment. After a 2-week drug-free interval, the synthesis rate was completely restored in both areas, and some subjects even showed upregulation of synthesis in previously steroid-treated skin.Continuous hydrocortisone for 3 weeks markedly decreases collagen propeptides and corresponding mRNA in human skin. Intermittent hydrocortisone has a less marked effect on the collagen synthesis rate.
Antiviral vaccines/cancer prophylactics?
Authors: B. Merz
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physician's assistant in general practice
Authors: K. Hambly
Journal: BMJ (1980)

doses of chlorpromazine intravenously had an initial reduction in high pressure that was followed by a severe pressure drop and a fatal outcome.We feel like Dr Young and colleagues that the hypotensive effect of phenothiazines, to which group chlorpromazine belongs, is not well known among physicians, and we once again would caution against too high initial doses of these drugs when used in emergency treatment of severe hypertension.
Darier's disease presenting as isolated hyperkeratosis of the breast
Authors: D.A. Fitzgerald, M.S. Lewis-Jones
Journal: British Journal of Dermatology (1997)

Journal Article Darier's disease presenting as isolated hyperkeratosis of the breast Get access D.A. Fitzgerald, D.A. Fitzgerald Department of Dermatology, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, U.K. Search for other works by this author on: Oxford Academic Google Scholar M.S. Lewis‐Jones M.S. Lewis‐Jones Department of Dermatology, Wrexham Maelor Hospital, Wrexham, Clwyd, LL13 7TD, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 136, Issue 2, 1 February 1997, Page 290, https://doi.org/10.1111/j.1365-2133.1997.tb14920.x Published: 01 February 1997
Gene Patenting — The Supreme Court Finally Speaks
Authors: Aaron S. Kesselheim, Robert M. Cook-Deegan, David E. Winickoff, Michelle M. Mello
Journal: New England Journal of Medicine (2013)

In June 2013, the U.S. Supreme Court unanimously ruled that the patents on BRCA1 and BRCA2 held by Myriad were not valid because human genes are products of nature and therefore not patentable. The authors discuss the implications of this long-awaited decision.